دورية أكاديمية
Real-World Effectiveness and Safety of Two-Drug Single Pill Combinations of Antihypertensive Medications for Blood Pressure Management: A Follow-Up on Daily Cardiology Practice in Douala, Cameroon.
| العنوان: | Real-World Effectiveness and Safety of Two-Drug Single Pill Combinations of Antihypertensive Medications for Blood Pressure Management: A Follow-Up on Daily Cardiology Practice in Douala, Cameroon. |
|---|---|
| المؤلفون: | Dzudie A; Service of Internal Medicine and Cardiology, Department of Internal Medicine and Subspecialties, Douala General Hospital, 4856, Douala, Cameroon. aitdzudie@yahoo.com.; Lown Scholar Programs, Cardiovascular Health, Harvard T H Chan School of Public Health, Boston, USA. aitdzudie@yahoo.com.; Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon. aitdzudie@yahoo.com., Barche B; Clinical Research Education Networking & Consultancy (CRENC), Douala, Cameroon., Zomene F; Clinical Research Education Networking & Consultancy (CRENC), Douala, Cameroon., Ebasone PV; Clinical Research Education Networking & Consultancy (CRENC), Douala, Cameroon., Nkoke C; Faculty of Health Sciences, University of Buea, Buea, Cameroon., Mouliom S; Service of Internal Medicine and Cardiology, Department of Internal Medicine and Subspecialties, Douala General Hospital, 4856, Douala, Cameroon.; Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon., Sidikatou D; Faculty of Health Sciences, University of Buea, Buea, Cameroon., Lade V; Service of Internal Medicine and Cardiology, Department of Internal Medicine and Subspecialties, Douala General Hospital, 4856, Douala, Cameroon., Ngote H; Service of Internal Medicine and Cardiology, Department of Internal Medicine and Subspecialties, Douala General Hospital, 4856, Douala, Cameroon., Njankouo YM; Service of Internal Medicine and Cardiology, Department of Internal Medicine and Subspecialties, Douala General Hospital, 4856, Douala, Cameroon.; Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon., Mbatchou BH; Service of Internal Medicine and Cardiology, Department of Internal Medicine and Subspecialties, Douala General Hospital, 4856, Douala, Cameroon.; Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon., Kamdem F; Service of Internal Medicine and Cardiology, Department of Internal Medicine and Subspecialties, Douala General Hospital, 4856, Douala, Cameroon.; Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon., Njebet J; Douala Cardiovascular Center, Douala, Cameroon., Kengne AP; Non-Communicable Diseases Research Unit, South African Medical Research Council, Francie Van Zijl Drive Parowvallei, Tygerberg, PO Box 19070, Cape Town, 7505, South Africa., Choukem SP; Service of Internal Medicine and Cardiology, Department of Internal Medicine and Subspecialties, Douala General Hospital, 4856, Douala, Cameroon.; Department of Internal Medicine and Specialties, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon. |
| المصدر: | Advances in therapy [Adv Ther] 2023 May; Vol. 40 (5), pp. 2282-2295. Date of Electronic Publication: 2023 Mar 14. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther |
| أسماء مطبوعة: | Publication: New York : Springer Healthcare Communications, 2008- : Health Communications Inc. Original Publication: Metuchen, N.J. : Health Communications Inc., c1984- |
| مواضيع طبية MeSH: | Hypertension*/epidemiology , Cardiology*, Humans ; Middle Aged ; Antihypertensive Agents/adverse effects ; Blood Pressure ; Cameroon ; Follow-Up Studies ; Calcium Channel Blockers/adverse effects ; Diuretics ; Drug Combinations |
| مستخلص: | Introduction: Hypertension is the leading cause of morbidity and mortality in sub-Saharan Africa (SSA). Current guidelines recommend using two or more antihypertensive agents in single pill combinations (SPCs) to treat hypertension, but data from African patients that support these recommendations are lacking. We assessed the effectiveness and tolerance of three SPCs in lowering blood pressure (BP) amongst hypertensive patients in Douala. Method: All patients included in the hypertension registry of the Douala General Hospital and the Douala Cardiovascular Center between January 2010 and May 2020, and receiving a two-drug SPCs (renin-angiotensin system inhibitors (RAASi) + diuretics (DIU), calcium channel blockers (CCB) + RAASi, or DIU + CCB) were tracked from baseline through 16 weeks. Our primary outcome was a decrease in systolic BP (SBP) from baseline up to 16 weeks after initiation of treatment. A mixed linear repeated model was used to evaluate the change of SBP from baseline to week 16, while controlling for age, gender, and baseline SBP. Statistical significance was set at p < 0.05. Results: Of 377 participants on two-drug SPCs, 123 were on CCB + DIU, 96 on RAASi + CCB, and 158 on RAASi + DIU. The mean age was 54.6 (± 11.2) years. At baseline, participants on RAASi + CCB presented with slightly higher SBP compared to the other two groups. Overall, the SBP decreased by 34.3 (± 14.2) mmHg from baseline values and this was comparable across the three groups of SPCs (p = 0.118). The control rate after 16 weeks of follow-up was 62.3% with no significant difference between groups. The occurrence of adverse events was 3.4% and was comparable among the three groups. Conclusion: The three two-drug SPCs were highly effective in reducing and controlling BP with low and similar rates of adverse effects. Long-term data documenting safety and whether these agents exert a differential cardiovascular effect in addition to and independent of their BP-lowering effect are needed for SSA populations. (© 2023. The Author(s).) |
| References: | Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–60. http://www.thelancet.com/article/S0140673612617668/fulltext . World Hypertension Day 2022—PAHO/WHO | Pan American Health Organization. https://www.paho.org/en/campaigns/world-hypertension-day-2022 . Accessed 11 Sep 2022. Nguyen TN, Chow CK. Global and national high blood pressure burden and control. Lancet. 2021;398:932–3. (PMID: 10.1016/S0140-6736(21)01688-334450082) Kola LD, Sumaili EK, Krzesinski J-M. How to treat hypertension in blacks: review of the evidence. Acta Clin Belg. 2009;64:466–76. (PMID: 10.1179/acb.2009.08220101869) Degli Esposti L, Perrone V, Veronesi C, et al. Modifications in drug adherence after switch to fixed-dose combination of perindopril/amlodipine in clinical practice. Results of a large-scale Italian experience. The amlodipine-perindopril in real settings (AMPERES) study. Curr Med Res Opin. 2018;34:1571–7. https://pubmed.ncbi.nlm.nih.gov/29376432/ . Liakos CI, Papadopoulos DP, Kotsis VT. Adherence to treatment, safety, tolerance, and effectiveness of perindopril/amlodipine fixed-dose combination in greek patients with hypertension and stable coronary artery disease: a pan-hellenic prospective observational study of daily clinical practice. Am J Cardiovasc Drugs. 2017;17:391–8. https://pubmed.ncbi.nlm.nih.gov/28466368/ . Mancia G, Rea F, Corrao G, Grassi G. Two-drug combinations as first-step antihypertensive treatment. Circ Res. 2019;124:1113–23. (PMID: 10.1161/CIRCRESAHA.118.31329430920930) Williams B, Masera G. 2018 ESC/ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the. Eur Heart J. 2018 www.wjpr.net . Accessed 17 Nov 2019. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334–57. https://doi.org/10.1161/hypertensionaha.120.15026 . Laurent S. Antihypertensive drugs. Pharmacol Res. 2017;124:116–25. (PMID: 10.1016/j.phrs.2017.07.02628780421) Jones ESW, Damasceno A, Ogola EN, Ojji DB, Dzudie A, Rayner BL. PASCAR commentary on the International Society of Hypertension global guidelines 2020: relevance to sub-Saharan Africa. Cardiovasc J Afr. 2020;31:325–30. https://pubmed.ncbi.nlm.nih.gov/33404583/ . Sareli P, Radevski IV, Valtchanova ZP, et al. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa. Arch Intern Med. 2001;161:965–71. https://pubmed.ncbi.nlm.nih.gov/11295959/ . Mengesha HG, Welegerima AH, Hadgu A, et al. Comparative effectiveness of antihypertensive drugs prescribed in Ethiopian healthcare practice: a pilot prospective, randomized, open label study. PLoS One. 2018;13:e0203166. Seeley A, Prynn J, Perera R, Street R, Davis D, Etyang AO. Pharmacotherapy for hypertension in Sub-Saharan Africa: a systematic review and network meta-analysis. BMC Med. 2020;18:1–11. https://doi.org/10.1186/s12916-020-01530-z . Iyalomhe GBS, Omogbai EKI, Isah AO, Iyalomhe OOB, Dada FL, Iyalomhe SI. Efficacy of initiating therapy with amlodipine and hydrochlorothiazide or their combination in hypertensive Nigerians. Clin Exp Hypertens. 2013;35:620–7. https://pubmed.ncbi.nlm.nih.gov/23510493/ . Ojji DB, Mayosi B, Francis V, et al. Comparison of dual therapies for lowering blood pressure in Black Africans. N Engl J Med. 2019;380:2429–39. https://doi.org/10.1056/NEJMoa1901113 . Mbanya A, Ackbarkhan A, Mittoo MY, et al. Use of perindopril arginine/indapamide/amlodipine in the management of hypertension in two sub-Saharan African Island countries of Madagascar and Mauritius. Adv Ther. 2022;39:2850–61. (PMID: 10.1007/s12325-022-02134-0354384489122888) Dzudie A, Fomo MF, Teuwafeu DG, et al. Prescription of pharmacotherapy and blood pressure control among hypertensive outpatients in two semi-urban hospitals in Cameroon: a cross-sectional study. Pan Afr Med J. 2020;37:122. (PMID: 10.11604/pamj.2020.37.122.21156334251557755361) Dzudie A, Rayner B, Ojji D, et al. Roadmap to achieve 25% hypertension control in Africa by 2025. Glob Heart. 2018;13:45–59. https://pubmed.ncbi.nlm.nih.gov/29042191/ . Ajayi SO, Ekrikpo UE, Ekanem AM, et al. Prevalence of chronic kidney disease as a marker of hypertension target organ damage in Africa: a systematic review and meta-analysis. Int J Hypertens. 2021. https://doi.org/10.1155/2021/7243523 . (PMID: 10.1155/2021/7243523346714908523261) Schutte AE, Botha S, Fourie CMT, et al. Recent advances in understanding hypertension development in sub-Saharan Africa. J Hum Hypertens. 2017;31:491–500. https://www.nature.com/articles/jhh201718 . Salam A, Huffman MD, Kanukula R, et al. Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: an overview of efficacy, safety, and cost. J Clin Hyperten. 2020;22:1769–79. https://doi.org/10.1111/jch.14009 . McInnes GT. “Size is not everything” The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Brit J Diabetes Vasc Dis. 2003;3:263–7. https://www.researchgate.net/publication/244920566_The_ALLHAT_Officers_and_Coordinators_for_the_ALLHAT_Collaborative_Research_Group_Major_outcomes_in_high-risk_hypertensive_patients_randomized_to_angiotensin-converting_enzyme_inhibitor_or_calcium_chan . Accessed 27 Sep 2022. Ojji DB, Libhaber E, Atherton JJ, Abdullahi B, Nwankwo A, Sliwa K. Risk-factor profile and comorbidities in 2398 patients with newly diagnosed hypertension from the abuja heart study. Medicine. Medicine (Baltimore). 2015;94:e1660. https://pubmed.ncbi.nlm.nih.gov/26426662/ . Ngango JM, Omole OB. Prevalence and sociodemographic correlates of cardiovascular risk factors among patients with hypertension in South African primary care. Cardiovasc J Afr. 2018;29:344–51. https://pubmed.ncbi.nlm.nih.gov/31199426/ . |
| فهرسة مساهمة: | Keywords: Calcium channel blocker; Diuretic; Effectiveness; Hypertension; Real-world data; Renin–angiotensin system inhibitors; Single pill combination |
| المشرفين على المادة: | 0 (Antihypertensive Agents) 0 (Calcium Channel Blockers) 0 (Diuretics) 0 (Drug Combinations) |
| تواريخ الأحداث: | Date Created: 20230314 Date Completed: 20230517 Latest Revision: 20230822 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10129918 |
| DOI: | 10.1007/s12325-023-02461-w |
| PMID: | 36917430 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1865-8652 |
|---|---|
| DOI: | 10.1007/s12325-023-02461-w |